SG11202006782YA - Topical formulations comprising tofacitinib - Google Patents
Topical formulations comprising tofacitinibInfo
- Publication number
- SG11202006782YA SG11202006782YA SG11202006782YA SG11202006782YA SG11202006782YA SG 11202006782Y A SG11202006782Y A SG 11202006782YA SG 11202006782Y A SG11202006782Y A SG 11202006782YA SG 11202006782Y A SG11202006782Y A SG 11202006782YA SG 11202006782Y A SG11202006782Y A SG 11202006782YA
- Authority
- SG
- Singapore
- Prior art keywords
- tofacitinib
- topical formulations
- topical
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862624567P | 2018-01-31 | 2018-01-31 | |
| PCT/US2019/014524 WO2019152232A1 (en) | 2018-01-31 | 2019-01-22 | Topical formulations comprising tofacitinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202006782YA true SG11202006782YA (en) | 2020-08-28 |
Family
ID=67393025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006782YA SG11202006782YA (en) | 2018-01-31 | 2019-01-22 | Topical formulations comprising tofacitinib |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10960006B2 (en) |
| EP (1) | EP3746086A4 (en) |
| JP (1) | JP7324210B2 (en) |
| KR (1) | KR20200128657A (en) |
| CN (1) | CN111670036A (en) |
| AU (1) | AU2019213835A1 (en) |
| BR (1) | BR112020015688A8 (en) |
| CA (1) | CA3089108A1 (en) |
| SG (1) | SG11202006782YA (en) |
| TW (1) | TW201940174A (en) |
| WO (1) | WO2019152232A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210212931A1 (en) * | 2018-01-31 | 2021-07-15 | Twi Pharmaceuticals, Inc. | Topical formulations comprising tofacitinib |
| WO2019236596A1 (en) * | 2018-06-04 | 2019-12-12 | Chemistryrx. | Topical compositions for stimulating hair growth |
| US20190381046A1 (en) * | 2018-06-14 | 2019-12-19 | Andrew HANNA | Tofacitinib and baclofen compositions and applications |
| US20200009077A1 (en) * | 2018-07-03 | 2020-01-09 | TRUETIVA, Inc. | Compositions for treating dermatological diseases |
| CA3157594A1 (en) * | 2019-11-08 | 2021-05-14 | Nitin JOSHI | Topical delivery of tofacitinib using ionic liquid |
| US11766438B2 (en) * | 2020-04-24 | 2023-09-26 | Slayback Pharma Llc | Pharmaceutical compositions of tofacitinib for oral administration |
| CN113712919A (en) * | 2020-05-25 | 2021-11-30 | 南京帝昌医药科技有限公司 | Preparation of tofacitinib citrate spray for treating alopecia |
| WO2022022434A1 (en) * | 2020-07-27 | 2022-02-03 | 杭州和正医药有限公司 | Pharmaceutical composition and preparation containing pharmaceutically acceptable salt of tofacitinib and use thereof |
| CN111728953B (en) * | 2020-07-29 | 2023-08-08 | 中国科学院上海药物研究所 | Sustained release preparation of tofacitinib or salt thereof and preparation method thereof |
| CN112402615A (en) * | 2020-11-11 | 2021-02-26 | 长沙晶易医药科技有限公司 | Compound external preparation for treating alopecia areata and preparation method thereof |
| US20220233544A1 (en) * | 2021-01-28 | 2022-07-28 | Chemistryrx | Treatments for skin conditions |
| CN113730335B (en) * | 2021-09-18 | 2023-07-28 | 中国药科大学 | Tofacitinib external pharmaceutical composition and application thereof |
| WO2023143345A1 (en) * | 2022-01-25 | 2023-08-03 | 杭州和正医药有限公司 | Tofacitinib-containing pharmaceutical composition for topical application, preparation, and use thereof |
| CN116942602B (en) * | 2023-09-20 | 2023-12-22 | 北京普祺医药科技股份有限公司 | Tofacitinib citrate pharmaceutical composition |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7301023B2 (en) * | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| US7776877B2 (en) * | 2007-06-22 | 2010-08-17 | Chemocentryx, Inc. | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides |
| KR20120115413A (en) | 2007-07-11 | 2012-10-17 | 화이자 인코포레이티드 | Pharmaceutical compositions and methods of treating dry eye disorders |
| US9198911B2 (en) * | 2010-11-02 | 2015-12-01 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
| WO2012099968A1 (en) * | 2011-01-19 | 2012-07-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating skin cancer associated diseases |
| EP2691395B1 (en) | 2011-03-28 | 2017-08-30 | ratiopharm GmbH | Processes for preparing tofacitinib salts |
| WO2012137111A1 (en) * | 2011-04-08 | 2012-10-11 | Pfizer Inc. | Crystalline and non- crystalline forms of tofacitinib, and a pharmaceutical composition comprising tofacitinib and a penetration enhancer |
| WO2014013014A1 (en) * | 2012-07-18 | 2014-01-23 | Fundació Privada Centre De Regulació Genòmica (Crg) | Jak inhibitors for activation of epidermal stem cell populations |
| JP6473134B2 (en) * | 2013-03-15 | 2019-02-20 | メディシス ファーマシューティカル コーポレイション | Flunisolide topical composition and method of treatment |
| EP3013336A1 (en) * | 2013-06-24 | 2016-05-04 | Tigercat Pharma Inc. | Use of nk-1 receptor antagonist serlopitant in pruritus |
| MY185593A (en) * | 2013-09-18 | 2021-05-24 | Bcn Peptides Sa | Cortistatin analogues for the treatment of inflammatory and/or immune diseases |
| EP3054959B1 (en) * | 2013-10-08 | 2020-01-08 | Promedior Inc. | Methods for treating fibrotic cancers |
| SG11201607881SA (en) * | 2014-03-31 | 2016-10-28 | Kirin Amgen Inc | Methods of treating nail and scalp psoriasis |
| WO2016025686A1 (en) * | 2014-08-15 | 2016-02-18 | Celgene Corporation | Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition |
| KR20180002838A (en) * | 2015-05-07 | 2018-01-08 | 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 | Methods and compositions for promoting hair growth |
| WO2017119928A1 (en) * | 2016-01-08 | 2017-07-13 | Abon Pharmaceuticals, Llc | Long acting injectable formulations |
-
2019
- 2019-01-22 CN CN201980011294.9A patent/CN111670036A/en active Pending
- 2019-01-22 CA CA3089108A patent/CA3089108A1/en active Pending
- 2019-01-22 WO PCT/US2019/014524 patent/WO2019152232A1/en unknown
- 2019-01-22 KR KR1020207022431A patent/KR20200128657A/en active Search and Examination
- 2019-01-22 AU AU2019213835A patent/AU2019213835A1/en active Pending
- 2019-01-22 BR BR112020015688A patent/BR112020015688A8/en unknown
- 2019-01-22 EP EP19747905.8A patent/EP3746086A4/en active Pending
- 2019-01-22 US US16/254,076 patent/US10960006B2/en active Active
- 2019-01-22 JP JP2020541671A patent/JP7324210B2/en active Active
- 2019-01-22 SG SG11202006782YA patent/SG11202006782YA/en unknown
- 2019-01-29 TW TW108103324A patent/TW201940174A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10960006B2 (en) | 2021-03-30 |
| TW201940174A (en) | 2019-10-16 |
| KR20200128657A (en) | 2020-11-16 |
| US20190231782A1 (en) | 2019-08-01 |
| BR112020015688A2 (en) | 2020-12-08 |
| CN111670036A (en) | 2020-09-15 |
| CA3089108A1 (en) | 2019-08-08 |
| JP2021512096A (en) | 2021-05-13 |
| BR112020015688A8 (en) | 2022-07-05 |
| EP3746086A4 (en) | 2021-10-20 |
| EP3746086A1 (en) | 2020-12-09 |
| AU2019213835A1 (en) | 2020-08-06 |
| WO2019152232A1 (en) | 2019-08-08 |
| JP7324210B2 (en) | 2023-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202006782YA (en) | Topical formulations comprising tofacitinib | |
| SG11202011761XA (en) | Nicotine formulation | |
| EP3328353A4 (en) | Topical skin formulations | |
| EP3735258A4 (en) | Topical skin care compositions | |
| EP3324925A4 (en) | Topical skin formulations | |
| IL266448A (en) | Topical detomidine formulations | |
| IL279284A (en) | Topical detomidine formulations | |
| GB2549418B (en) | Topical formulations comprising dimethicone macromers | |
| GB2586731B (en) | Topical skin care compositions | |
| IL280533A (en) | Topical composition | |
| IL287416A (en) | Topical formulation | |
| GB201904338D0 (en) | Fluorouracil-containing formulations | |
| EP3328354A4 (en) | Topical skin formulations | |
| PT4045038T (en) | New formulations | |
| IL277213A (en) | Topical composition | |
| EP3383912A4 (en) | Topical formulations | |
| IL290356A (en) | Larazotide formulations | |
| IL284691A (en) | Formulations | |
| PL3856128T3 (en) | Topical sunscreen formulation | |
| SG11202012165WA (en) | Formulations/compositions comprising ibrutinib | |
| IL284072A (en) | Topical compositions | |
| SG11202011823SA (en) | Activator-nucleator formulations | |
| GB201819028D0 (en) | Butanol-based formulations | |
| ZA202103782B (en) | Teriflunomide topical pharmaceutical compositions | |
| GB201911063D0 (en) | Formulations |